Cargando…

A cohort study of membranous nephropathy, primary or secondary

BACKGROUND: Although IgG4 deposit against phospholipase A2 receptor (anti-PLA2R) is predominantly presented in the renal biopsy of patients with primary membranous nephropathy (MN), its diagnostic value of this immune complex has not been fully established. METHODS: In this cohort study, 108 biopsy-...

Descripción completa

Detalles Bibliográficos
Autores principales: Arghiani, Maryam, Zamani, Boshra Hasan, Nazemian, Fatemeh, Samadi, Sara, Afsharian, Malihe Saber, Habibzadeh, Mahmoud, Eslami, Saeid, Sabbagh, Mahin Ghorban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056567/
https://www.ncbi.nlm.nih.gov/pubmed/33874909
http://dx.doi.org/10.1186/s12882-021-02338-6
_version_ 1783680674046148608
author Arghiani, Maryam
Zamani, Boshra Hasan
Nazemian, Fatemeh
Samadi, Sara
Afsharian, Malihe Saber
Habibzadeh, Mahmoud
Eslami, Saeid
Sabbagh, Mahin Ghorban
author_facet Arghiani, Maryam
Zamani, Boshra Hasan
Nazemian, Fatemeh
Samadi, Sara
Afsharian, Malihe Saber
Habibzadeh, Mahmoud
Eslami, Saeid
Sabbagh, Mahin Ghorban
author_sort Arghiani, Maryam
collection PubMed
description BACKGROUND: Although IgG4 deposit against phospholipase A2 receptor (anti-PLA2R) is predominantly presented in the renal biopsy of patients with primary membranous nephropathy (MN), its diagnostic value of this immune complex has not been fully established. METHODS: In this cohort study, 108 biopsy-proven MN patients with proteinuria were evaluated during two years follow up and were divided into primary and secondary groups. Renal biopsy specimens were pathologically assessed for IgG4 and PLA2R depositions by immunohistochemistry (IHC). Therefore, the relationships between staining severity, MN type and total proteinuria in all patients were determined. RESULTS: Of 108 patients, 73.1% had primary MN and 26.9% were diagnosed as secondary form. IHC staining in patients with primary MN was positive for PLA2R in 76 (96.2%) and IgG4 in 68 (86.1%). Cases with positive PLA2R expression had a significantly higher rate among patients with mild to moderate stages (P = 0.03). No significant relationship was found between intensity of PLA2R and IgG4 deposits with proteinuria and serum creatinine. Based on our data, double positivity/negativity of PLA2R and IgG4 expression adds prominent information to the clinical data and were found to be useful and robust biomarkers for detection of primary MN patients with high sensitivity and specificity (97.1 and 96.3% respectively, PPV = 98.5% and NPV = 92.9%). CONCLUSIONS: Simultaneously expression of PLA2R and IgG4 in renal biopsy specimens of patients with MN could possibly be used as a potential diagnostic method to distinguish primary from secondary MN and also pathological severity of the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-021-02338-6.
format Online
Article
Text
id pubmed-8056567
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80565672021-04-20 A cohort study of membranous nephropathy, primary or secondary Arghiani, Maryam Zamani, Boshra Hasan Nazemian, Fatemeh Samadi, Sara Afsharian, Malihe Saber Habibzadeh, Mahmoud Eslami, Saeid Sabbagh, Mahin Ghorban BMC Nephrol Research BACKGROUND: Although IgG4 deposit against phospholipase A2 receptor (anti-PLA2R) is predominantly presented in the renal biopsy of patients with primary membranous nephropathy (MN), its diagnostic value of this immune complex has not been fully established. METHODS: In this cohort study, 108 biopsy-proven MN patients with proteinuria were evaluated during two years follow up and were divided into primary and secondary groups. Renal biopsy specimens were pathologically assessed for IgG4 and PLA2R depositions by immunohistochemistry (IHC). Therefore, the relationships between staining severity, MN type and total proteinuria in all patients were determined. RESULTS: Of 108 patients, 73.1% had primary MN and 26.9% were diagnosed as secondary form. IHC staining in patients with primary MN was positive for PLA2R in 76 (96.2%) and IgG4 in 68 (86.1%). Cases with positive PLA2R expression had a significantly higher rate among patients with mild to moderate stages (P = 0.03). No significant relationship was found between intensity of PLA2R and IgG4 deposits with proteinuria and serum creatinine. Based on our data, double positivity/negativity of PLA2R and IgG4 expression adds prominent information to the clinical data and were found to be useful and robust biomarkers for detection of primary MN patients with high sensitivity and specificity (97.1 and 96.3% respectively, PPV = 98.5% and NPV = 92.9%). CONCLUSIONS: Simultaneously expression of PLA2R and IgG4 in renal biopsy specimens of patients with MN could possibly be used as a potential diagnostic method to distinguish primary from secondary MN and also pathological severity of the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12882-021-02338-6. BioMed Central 2021-04-19 /pmc/articles/PMC8056567/ /pubmed/33874909 http://dx.doi.org/10.1186/s12882-021-02338-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Arghiani, Maryam
Zamani, Boshra Hasan
Nazemian, Fatemeh
Samadi, Sara
Afsharian, Malihe Saber
Habibzadeh, Mahmoud
Eslami, Saeid
Sabbagh, Mahin Ghorban
A cohort study of membranous nephropathy, primary or secondary
title A cohort study of membranous nephropathy, primary or secondary
title_full A cohort study of membranous nephropathy, primary or secondary
title_fullStr A cohort study of membranous nephropathy, primary or secondary
title_full_unstemmed A cohort study of membranous nephropathy, primary or secondary
title_short A cohort study of membranous nephropathy, primary or secondary
title_sort cohort study of membranous nephropathy, primary or secondary
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056567/
https://www.ncbi.nlm.nih.gov/pubmed/33874909
http://dx.doi.org/10.1186/s12882-021-02338-6
work_keys_str_mv AT arghianimaryam acohortstudyofmembranousnephropathyprimaryorsecondary
AT zamaniboshrahasan acohortstudyofmembranousnephropathyprimaryorsecondary
AT nazemianfatemeh acohortstudyofmembranousnephropathyprimaryorsecondary
AT samadisara acohortstudyofmembranousnephropathyprimaryorsecondary
AT afsharianmalihesaber acohortstudyofmembranousnephropathyprimaryorsecondary
AT habibzadehmahmoud acohortstudyofmembranousnephropathyprimaryorsecondary
AT eslamisaeid acohortstudyofmembranousnephropathyprimaryorsecondary
AT sabbaghmahinghorban acohortstudyofmembranousnephropathyprimaryorsecondary
AT arghianimaryam cohortstudyofmembranousnephropathyprimaryorsecondary
AT zamaniboshrahasan cohortstudyofmembranousnephropathyprimaryorsecondary
AT nazemianfatemeh cohortstudyofmembranousnephropathyprimaryorsecondary
AT samadisara cohortstudyofmembranousnephropathyprimaryorsecondary
AT afsharianmalihesaber cohortstudyofmembranousnephropathyprimaryorsecondary
AT habibzadehmahmoud cohortstudyofmembranousnephropathyprimaryorsecondary
AT eslamisaeid cohortstudyofmembranousnephropathyprimaryorsecondary
AT sabbaghmahinghorban cohortstudyofmembranousnephropathyprimaryorsecondary